Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Receivables: 2022-2024

Historic Change in Receivables for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $47.2 million.

  • Axsome Therapeutics' Change in Receivables fell 161.75% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year increase of 58.51%. This contributed to the annual value of $47.2 million for FY2024, which is 17.40% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Change in Receivables of $47.2 million as of FY2024, which was down 17.40% from $57.1 million recorded in FY2023.
  • Over the past 5 years, Axsome Therapeutics' Change in Receivables peaked at $57.1 million during FY2023, and registered a low of $37.7 million during FY2022.
  • Over the past 3 years, Axsome Therapeutics' median Change in Receivables value was $47.2 million (recorded in 2024), while the average stood at $47.3 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Change in Receivables soared by 51.52% in 2023, and later declined by 17.40% in 2024.
  • Over the past 3 years, Axsome Therapeutics' Change in Receivables (Yearly) stood at $37.7 million in 2022, then soared by 51.52% to $57.1 million in 2023, then fell by 17.40% to $47.2 million in 2024.